세계의 유전자 편집 시장 : 기술, 용도, 최종 사용자, 제품 및 서비스, 제공 방법별 예측(2025-2030년)

The Gene Editing Market was valued at USD 7.89 billion in 2023, expected to reach USD 9.18 billion in 2024, and is projected to grow at a CAGR of 17.81%, to USD 24.87 billion by 2030.

Gene editing, defined as a method of making specific and intentional changes to the DNA sequence of living organisms, holds immense potential across various sectors due to its precision, efficiency, and broad application scope. The necessity of gene editing is rooted in its ability to address critical challenges, such as correcting genetic disorders, improving agricultural productivity, and developing novel therapies in healthcare. Applications span sectors from biomedical research, agriculture, and drug discovery to regenerative medicine, making it a versatile tool in modern science. End-use scope is vast, including pharmaceuticals, biotechnology, agriculture, and academic research institutions. Market growth is driven by advances in gene-editing technologies like CRISPR-Cas9, increased funding from public and private sectors, and an escalating demand for genetically modified crops and gene therapies. However, ethical concerns, regulatory challenges, and high costs are significant limitations curbing rapid market adoption. Moreover, the complexity of CRISPR technology and off-target effects present technical challenges that hinder widespread use. Key opportunities lie in expanding applications beyond traditional uses to encompass areas like synthetic biology and biofuels. To capitalize on these potential opportunities, businesses should focus on innovations that reduce costs and improve the precision of gene-editing techniques, thus enhancing their applicability and public acceptance. The integration of artificial intelligence and machine learning to predict gene-edited outcomes and potential CRISPR libraries to expedite research offer promising areas of innovation. However, stringent regulatory landscapes across different regions necessitate strategic navigation to enable smoother market entry and adoption. The gene editing market is intensely competitive, characterized by rapid technological advancements and a need for constant innovation. Thus, widespread collaboration between public institutions, private players, and regulatory bodies is essential to harness the full potential and guide ethical implementation of gene-editing technologies.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Gene Editing Market

The Gene Editing Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increased prevalence of genetic diseases and disorders requiring innovative treatment solutions
  • Growing adoption of CRISPR and other advanced technologies in clinical applications
  • Expanding governmental and private sector funding for genomics and gene therapy research
• Market Restraints
  • High costs and ethical concerns regarding gene-editing technologies
• Market Opportunities
  • Integration of gene editing with other advanced technologies such as artificial intelligence (AI)
  • Rising investment in genetic research and biotechnology to drive gene editing advancements
• Market Challenges
  • Technological and ethical challenges associated with gene editing

Porter's Five Forces: A Strategic Tool for Navigating the Gene Editing Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Gene Editing Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Gene Editing Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Gene Editing Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Gene Editing Market

A detailed market share analysis in the Gene Editing Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Gene Editing Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Gene Editing Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Gene Editing Market

A strategic analysis of the Gene Editing Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Gene Editing Market, highlighting leading vendors and their innovative profiles. These include Bayer CropScience, Beam Therapeutics, Bluebird Bio, Caribou Biosciences, Cellectis, Cibus, CRISPR Therapeutics, Editas Medicine, Genscript Biotech, Horizon Discovery, Inscripta, Intellia Therapeutics, Lonza Group, Pioneer Hi-Bred International Inc., Precision Biosciences, Regeneron Pharmaceuticals, Sangamo Therapeutics, Syngenta AG, Synthego, and Thermo Fisher Scientific.

Market Segmentation & Coverage

This research report categorizes the Gene Editing Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Technology, market is studied across CRISPR, Meganucleases, TALENs, and Zinc Finger Nucleases (ZFNs).
• Based on Application, market is studied across Agricultural Applications, Clinical Applications, and Research Applications. The Agricultural Applications is further studied across Crop Enhancement and Livestock Genetic Engineering. The Clinical Applications is further studied across Cell Line Engineering and Gene Therapy. The Research Applications is further studied across Gene Function Studies and Stem Cell Research.
• Based on End User, market is studied across Academic & Research Institutes, Contract Research Organizations, and Pharmaceutical & Biotechnology Companies.
• Based on Product & Service, market is studied across Consumables, Instruments, and Services. The Consumables is further studied across Kits & Reagents and Libraries.
• Based on Delivery Method, market is studied across Biological Methods and Physical Methods. The Biological Methods is further studied across Non-Viral Methods and Viral Vectors. The Physical Methods is further studied across Electroporation and Microinjection.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increased prevalence of genetic diseases and disorders requiring innovative treatment solutions
    • 5.1.1.2. Growing adoption of CRISPR and other advanced technologies in clinical applications
    • 5.1.1.3. Expanding governmental and private sector funding for genomics and gene therapy research
  • 5.1.2. Restraints
    • 5.1.2.1. High costs and ethical concerns regarding gene-editing technologies
  • 5.1.3. Opportunities
    • 5.1.3.1. Integration of gene editing with other advanced technologies such as artificial intelligence (AI)

• 5.1.3.2. Rising investment in genetic research and biotechnology to drive gene editing advancements

• 5.1.4. Challenges
  • 5.1.4.1. Technological and ethical challenges associated with gene editing
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Gene Editing Market, by Technology

• 6.1. Introduction
• 6.2. CRISPR
• 6.3. Meganucleases
• 6.4. TALENs
• 6.5. Zinc Finger Nucleases (ZFNs)

7. Gene Editing Market, by Application

• 7.1. Introduction
• 7.2. Agricultural Applications
  • 7.2.1. Crop Enhancement
  • 7.2.2. Livestock Genetic Engineering
• 7.3. Clinical Applications
  • 7.3.1. Cell Line Engineering
  • 7.3.2. Gene Therapy
• 7.4. Research Applications
  • 7.4.1. Gene Function Studies
  • 7.4.2. Stem Cell Research

8. Gene Editing Market, by End User

• 8.1. Introduction
• 8.2. Academic & Research Institutes
• 8.3. Contract Research Organizations
• 8.4. Pharmaceutical & Biotechnology Companies

9. Gene Editing Market, by Product & Service

• 9.1. Introduction
• 9.2. Consumables
  • 9.2.1. Kits & Reagents
  • 9.2.2. Libraries
• 9.3. Instruments
• 9.4. Services

10. Gene Editing Market, by Delivery Method

• 10.1. Introduction
• 10.2. Biological Methods
  • 10.2.1. Non-Viral Methods
  • 10.2.2. Viral Vectors
• 10.3. Physical Methods
  • 10.3.1. Electroporation
  • 10.3.2. Microinjection

11. Americas Gene Editing Market

• 11.1. Introduction
• 11.2. Argentina
• 11.3. Brazil
• 11.4. Canada
• 11.5. Mexico
• 11.6. United States

12. Asia-Pacific Gene Editing Market

• 12.1. Introduction
• 12.2. Australia
• 12.3. China
• 12.4. India
• 12.5. Indonesia
• 12.6. Japan
• 12.7. Malaysia
• 12.8. Philippines
• 12.9. Singapore
• 12.10. South Korea
• 12.11. Taiwan
• 12.12. Thailand
• 12.13. Vietnam

13. Europe, Middle East & Africa Gene Editing Market

• 13.1. Introduction
• 13.2. Denmark
• 13.3. Egypt
• 13.4. Finland
• 13.5. France
• 13.6. Germany
• 13.7. Israel
• 13.8. Italy
• 13.9. Netherlands
• 13.10. Nigeria
• 13.11. Norway
• 13.12. Poland
• 13.13. Qatar
• 13.14. Russia
• 13.15. Saudi Arabia
• 13.16. South Africa
• 13.17. Spain
• 13.18. Sweden
• 13.19. Switzerland
• 13.20. Turkey
• 13.21. United Arab Emirates
• 13.22. United Kingdom

14. Competitive Landscape

• 14.1. Market Share Analysis, 2023
• 14.2. FPNV Positioning Matrix, 2023
• 14.3. Competitive Scenario Analysis
• 14.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Bayer CropScience
• 2. Beam Therapeutics
• 3. Bluebird Bio
• 4. Caribou Biosciences
• 5. Cellectis
• 6. Cibus
• 7. CRISPR Therapeutics
• 8. Editas Medicine
• 9. Genscript Biotech
• 10. Horizon Discovery
• 11. Inscripta
• 12. Intellia Therapeutics
• 13. Lonza Group
• 14. Pioneer Hi-Bred International Inc.
• 15. Precision Biosciences
• 16. Regeneron Pharmaceuticals
• 17. Sangamo Therapeutics
• 18. Syngenta AG
• 19. Synthego
• 20. Thermo Fisher Scientific